Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Frontiers in Pharmacology
|
October 19, 2018
Using Machine Learning to Predict Synergistic Antimalarial Compound Combinations With Novel Structures
Daniel J Mason, Richard T Eastman, Richard P I Lewis, et al.
Neuropharmacology
|
May 25, 2018
Repurposing available drugs for neurodevelopmental disorders: The fragile X experience
Michael R Tranfaglia, Clare Thibodeaux, Daniel J Mason, et al.
Journal of Medicinal Chemistry
|
April 7, 2017
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure
Daniel J Mason, Ian Stott, Stephanie Ashenden, et al.
Drug Discovery Today
|
September 12, 2015
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives
Krishna C Bulusu, Rajarshi Guha, Daniel J Mason, et al.
BMC Cancer
|
April 1, 2017
Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity
C P Baburajeev, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, et al.
Plos One
|
October 1, 2014
Synthesis and characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in acute myeloid leukemia cell lines
Hosadurga K Keerthy, Manoj Garg, Chakrabhavi D Mohan, et al.
Brain Communications
|
January 16, 2024
A novel combination treatment for fragile X syndrome predicted using computational methods
Wayne Chadwick, Ivan Angulo-Herrera, Patricia Cogram, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 17, 2015
Novel synthetic coumarins that targets NF-κB in Hepatocellular carcinoma
Mahabaleshwaraiah Neelgundmath, Koragere Rajashekar Dinesh, Chakrabhavi Dhananjaya Mohan, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 7, 2015
Synthesis and characterization of novel oxazines and demonstration that they specifically target cyclooxygenase 2
V Srinivas, Chakrabhavi Dhananjaya Mohan, C P Baburajeev, et al.
EMBO Molecular Medicine
|
December 24, 2025
Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma
Katarzyna Radke, Kristina Aaltonen, Erick A Muciño-Olmos, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Frontiers in Pharmacology
|
October 19, 2018
Using Machine Learning to Predict Synergistic Antimalarial Compound Combinations With Novel Structures
Daniel J Mason, Richard T Eastman, Richard P I Lewis, et al.
Neuropharmacology
|
May 25, 2018
Repurposing available drugs for neurodevelopmental disorders: The fragile X experience
Michael R Tranfaglia, Clare Thibodeaux, Daniel J Mason, et al.
Journal of Medicinal Chemistry
|
April 7, 2017
Prediction of Antibiotic Interactions Using Descriptors Derived from Molecular Structure
Daniel J Mason, Ian Stott, Stephanie Ashenden, et al.
Drug Discovery Today
|
September 12, 2015
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives
Krishna C Bulusu, Rajarshi Guha, Daniel J Mason, et al.
BMC Cancer
|
April 1, 2017
Identification of Novel Class of Triazolo-Thiadiazoles as Potent Inhibitors of Human Heparanase and their Anticancer Activity
C P Baburajeev, Chakrabhavi Dhananjaya Mohan, Shobith Rangappa, et al.
Plos One
|
October 1, 2014
Synthesis and characterization of novel 2-amino-chromene-nitriles that target Bcl-2 in acute myeloid leukemia cell lines
Hosadurga K Keerthy, Manoj Garg, Chakrabhavi D Mohan, et al.
Brain Communications
|
January 16, 2024
A novel combination treatment for fragile X syndrome predicted using computational methods
Wayne Chadwick, Ivan Angulo-Herrera, Patricia Cogram, et al.
Bioorganic & Medicinal Chemistry Letters
|
January 17, 2015
Novel synthetic coumarins that targets NF-κB in Hepatocellular carcinoma
Mahabaleshwaraiah Neelgundmath, Koragere Rajashekar Dinesh, Chakrabhavi Dhananjaya Mohan, et al.
Bioorganic & Medicinal Chemistry Letters
|
June 7, 2015
Synthesis and characterization of novel oxazines and demonstration that they specifically target cyclooxygenase 2
V Srinivas, Chakrabhavi Dhananjaya Mohan, C P Baburajeev, et al.
EMBO Molecular Medicine
|
December 24, 2025
Repurposing statins and phenothiazines to treat chemoresistant neuroblastoma
Katarzyna Radke, Kristina Aaltonen, Erick A Muciño-Olmos, et al.
Page
of 1